Search clinical trials for: programmed cell death

Total 50638 results

GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
The Central Hospital of Lishui City

Not yet recruiting

Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLC

Carcinoma | Small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004)

Non-small Cell Lung Cancer

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Breast Neoplasms

Israel, United States, Taiwan
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

United States, Australia, Canada, Chile, Taiwan
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Pembrolizumab (MK-3475) Plus V940 in Participants With Bladder Cancer Post-Radical Resection (V940-005)

Bladder Cancer

Canada, Germany, Australia, United States, Poland, Spain, Chile, France
Pfizer

Recruiting

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Melanoma | Neoplasms | Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

Puerto Rico, Japan, United States
National Cancer Institute (NCI)

Recruiting

Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Small Cell Carcinoma of the Bladder | High Grade Neuroendocrine Tumors of the Urinary Tract

United States
Huabo Biopharm Co., Ltd.

Recruiting

A Study of HB0025 Injection in Patients With Advanced Renal Cancer

Renal Cancer

China
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Non-small Cell Lung Cancer (NSCLC)

Australia, United States, Turkey, Chile, Taiwan, Denmark, France, Spain
National Cancer Institute (NCI)

Not yet recruiting

Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Squamous Cell Carcinoma of the Penis | Renal Medullary Carcinoma | Squamous Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Bladder | Small Cell Carcinoma of the Urinary Tract | Squamous Cell Carcinoma of the Urinary Tract | Primary Adenocarcinoma of the Bladder | Primary Adenocarcinoma...

United States
Fudan University
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Tongji Hospital

Not yet recruiting

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Hepatocellular Carcinoma

China
Tongji Hospital

Not yet recruiting

Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion

Hepatocellular Carcinoma

China
Sun Yat-sen University

Not yet recruiting

bTAE-HAIC Combined With Lenvatinib and Sintilimab for Infiltrative Hepatocellular Carcinoma

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Sintilimab | Lenvatinib

China
Sun Yat-sen University

Not yet recruiting

bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC

Liver Diseases | Hepatocellular Carcinoma | Immunotherapy | Camrelizumab | Lenvatinib

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
National Cancer Institute (NCI)

Not yet recruiting

Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)

Adenocarcinoma of the Bladder | Squamous Cell Carcinoma of the Bladder | Testicular Germ Cell Tumors

United States
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-3475A (Pembrolizumab Formulated With MK-5180) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Squamous Cell Carcinoma

Japan
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Malaysia, United States, Netherlands, Turkey, France
Beijing Friendship Hospital

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for Locally Advanced Mid-low Rectal Cancer

Colorectal Neoplasms

China
AstraZeneca

Recruiting

A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients (TRITON)

Carcinoma, Non-Small-Cell Lung

United States
Qian Chu
Akeso Pharmaceuticals, Inc.

Recruiting

Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative (ACHELOUS)

Carcinoma, Non-Small-Cell Lung

China
Sun Yat-sen University

Recruiting

Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation (BCIRT-01)

Muscle-Invasive Bladder Carcinoma | Radiotherapy | Programmed Cell Death Protein 1 Inhibitor

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy

Magnetic Resonance Imaging | Head and Neck Squamous Cell Carcinoma | Neoadjuvant Therapy

China
Thomas Jefferson University

Recruiting

Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Locally Advanced Basal Cell Carcinoma

United States
Peking University Third Hospital

Not yet recruiting

Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors (SCARCE)

Advanced Solid Tumor | Efficacy | Safety | Stereotactic Body Radiotherapy | Immune Checkpoint Inhibitor

China
Casey Cosgrove

Recruiting

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recurrent Endometrial Serous Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Recruiting

Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Switzerland, United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States, Malaysia, Australia, Georgia, Israel
BioVersys AG

Recruiting

PK of BV100 in Patients VABP Suspected or Confirmed to be Due to CRAB

Ventilator Associated Pneumonia

Greece, Georgia, Hungary
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

Phase Ⅱ/Ⅲ Clinical Study of Tumor Treating Fields （EFE-P100）Combined With Docetaxel in the Treatment of Stage IV Non-small Cell Lung Cancer Patients With Disease Progression After Platinum-based Chemotherapy and Anti-programmed Death 1（PD-1)/Programmed Cell Death-Ligand 1(PD-L1) Antibody Treatment

Non-small Cell Lung Cancer (NSCLC)

China
BeiGene

Recruiting

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Spain, Malaysia, Italy, Canada, Thailand, Georgia, Brazil, Korea, Republic of, Singapore, Moldova, Republic of, Romania
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
Merck Sharp & Dohme LLC
Gilead Sciences

Recruiting

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Carcinoma, Non-Small-Cell Lung

China, Poland, Latvia, United States, Taiwan, Australia, Turkey, Germany, Israel, Korea, Republic of, Estonia, Romania, Chile, Italy, Brazil, Greece, Philippines, Canada, Japan, Malaysia, United Kingdom, Lithuania, Thailand, Peru
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)

Advanced or Metastatic Solid Tumors

Canada, Switzerland, United States
Regeneron Pharmaceuticals
BioNTech SE

Recruiting

Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ≥ 50%

Advanced Non-Small Cell Lung Cancer

United States, Korea, Republic of, Spain, Georgia, Taiwan, Germany, Turkey
Merck Sharp & Dohme LLC

Recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

Hodgkin Lymphoma

Australia, Israel, Korea, Republic of, Spain, Poland, Sweden, United Kingdom, Turkey, China, United States, Brazil, Germany, Belgium, France, Switzerland, Canada, Czechia, Chile, Argentina
Merck Sharp & Dohme LLC

Recruiting

A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)

Renal Cell Carcinoma

United States, Australia, Israel
Sohag University

Not yet recruiting

Expression of Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PDL-1) in Acute Lymphoblastic Leukemia in Pediatric

Acute Lymphoblastic Leukemia in Pediatric

Egypt
Tongji Hospital

Recruiting

Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC

Hepatocellular Carcinoma | Effects of Immunotherapy | Programmed Cell Death 1

China
Peking University

Not yet recruiting

Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC

Recruiting

A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)

Advanced or Metastatic Solid Tumors

United States, Canada, Israel, Netherlands
Merck Sharp & Dohme LLC

Recruiting

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Esophageal Squamous Cell Carcinoma (ESCC)

Japan, Korea, Republic of, Taiwan, Italy, Thailand, France, Turkey, Switzerland, Brazil, Singapore, Germany, Chile, Norway
Janssen Research & Development, LLC

Recruiting

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (TRIMM-3)

Relapsed/ Refractory Multiple Myeloma

United States, Germany, Spain, France
Institut de cancérologie Strasbourg Europe
Institut National de la Santé Et de la Recherche Médicale, France; Centre National...

Recruiting

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma (IPRICE)

Head and Neck Cancer

France
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)

Esophageal Squamous Cell Carcinoma

Japan, Korea, Republic of, China, Taiwan, Italy, Switzerland, Brazil, Germany, Singapore, Turkey, Thailand, Chile, Norway
Lei Li

Recruiting

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Cervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical Cancer

China
Lei Li

Recruiting

Tislelizumab and Radiotherapy for Recurrent Cervical Cancer

Recurrent Cervical Carcinoma | Radiotherapy | Immunotherapy | Survival Outcomes | Immune Checkpoint Inhibitors | Objective Response Rate | Metastatic Cervical Carcinoma | Tislelizumab | Persistent Cervical Carcinoma | Anti-programmed Cell Death Receptor 1

China

Search clinical trials for: programmed cell death

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations